Join
Live feed
·
PRReleasevia Quantisnow
Metagenomi Therapeutics Inc. logo

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

ByQuantisnow·Wall Street's wire, on your screen.
MGX· Metagenomi Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MGX (Metagenomi Therapeutics Inc.) and more on Quantisnow.